Amytrx Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Later Stage VC
  • (In Progress)

  • Latest Deal Amount
  • $28M

  • Investors
  • 2

Amytrx Therapeutics General Information

Description

Developer of anti-inflammatory peptide medicines intended to treat inflammation and metabolic disorders. company's medicines use cell-penetrating decoy peptides that selectively target leukocyte cells and AMTX-100 reversibly binds to the importin Alpha5, beta1 complex used by large, proinflammatory transcription factors to transport them into the cell's nucleus and binds to DNA or genes that then produce chemokines, cytokines and growth factors, enabling patients to get treatment for inflammation and metabolic syndromes safely.

Contact Information

Website
www.amytrx.com
Formerly Known As
AGH Therapeutics, HGA Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 40 Burton Hills Boulevard
  • Suite 260
  • Nashville, TN 37215
  • United States
+1 (502)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 40 Burton Hills Boulevard
  • Suite 260
  • Nashville, TN 37215
  • United States
+1 (502)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Amytrx Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC $28M In Progress Clinical Trials - Phase 2
3. Later Stage VC 31-Jan-2024 Completed Clinical Trials - Phase 2
2. Later Stage VC (Series A) 20-Sep-2020 $18M $18.6M Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) 01-Jul-2016 $600K $600K Completed Startup
To view Amytrx Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Amytrx Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of anti-inflammatory peptide medicines intended to treat inflammation and metabolic disorders. company's medic
Drug Discovery
Nashville, TN
4 As of 2025

Cambridge, MA
 

Bagsvaerd, Denmark
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Amytrx Therapeutics Competitors (4)

One of Amytrx Therapeutics’s 4 competitors is Alnylam Pharmaceuticals, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA
Novo Nordisk Corporation Bagsvaerd, Denmark
Eli Lilly Corporation Indianapolis, IN
Novartis Corporation Basel, Switzerland
To view Amytrx Therapeutics’s complete competitors history, request access »

Amytrx Therapeutics Patents

Amytrx Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4522119-A2 Formulations comprising short peptides and uses in the treatment of inflammatory or autoimmune diseases Pending 12-May-2022
CA-3230157-A1 Leukocyte-specific cell penetrating molecules Pending 23-Aug-2021
EP-4392051-A1 Leukocyte-specific cell penetrating molecules Pending 23-Aug-2021 C07K7/08

Amytrx Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amytrx Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Burch Investment Group Venture Capital Minority
Rugosa Partners Venture Capital Minority
To view Amytrx Therapeutics’s complete investors history, request access »

Amytrx Therapeutics FAQs

  • When was Amytrx Therapeutics founded?

    Amytrx Therapeutics was founded in 2014.

  • Where is Amytrx Therapeutics headquartered?

    Amytrx Therapeutics is headquartered in Nashville, TN.

  • What is the size of Amytrx Therapeutics?

    Amytrx Therapeutics has 4 total employees.

  • What industry is Amytrx Therapeutics in?

    Amytrx Therapeutics’s primary industry is Drug Discovery.

  • Is Amytrx Therapeutics a private or public company?

    Amytrx Therapeutics is a Private company.

  • What is Amytrx Therapeutics’s current revenue?

    The current revenue for Amytrx Therapeutics is .

  • How much funding has Amytrx Therapeutics raised over time?

    Amytrx Therapeutics has raised $49.6M.

  • Who are Amytrx Therapeutics’s investors?

    Burch Investment Group and Rugosa Partners have invested in Amytrx Therapeutics.

  • Who are Amytrx Therapeutics’s competitors?

    Alnylam Pharmaceuticals, Novo Nordisk, Eli Lilly, and Novartis are competitors of Amytrx Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »